Dr. Reddy's Laboratories Limited Stock

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:49 2024-04-12 am EDT 5-day change 1st Jan Change
6,084 INR -1.22% Intraday chart for Dr. Reddy's Laboratories Limited -1.47% +4.94%
Sales 2024 * 279B 3.34B Sales 2025 * 298B 3.58B Capitalization 1,026B 12.3B
Net income 2024 * 54.49B 653M Net income 2025 * 56.36B 676M EV / Sales 2024 * 3.42 x
Net cash position 2024 * 72.91B 874M Net cash position 2025 * 112B 1.35B EV / Sales 2025 * 3.06 x
P/E ratio 2024 *
18.8 x
P/E ratio 2025 *
18.2 x
Employees 25,863
Yield 2024 *
0.66%
Yield 2025 *
0.68%
Free-Float 91.52%
More Fundamentals * Assessed data
Dynamic Chart
Dr. Reddy's Launches Migraine Management Device Nerivio in Germany MT
Dr. Reddy's Launches Migraine Management Wearable in Germany MT
Asian Equities Traded in the US as American Depositary Receipts Start Week on Strong Note in Monday Trading MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Dr. Reddy's Laboratories, Bayer Collaborate to Distribute Second Brand of Heart Failure Drug in India MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading, End Week Lower MT
Bayer and Dr. Reddy's Sign A Marketing and Distribution Agreement for Second Brand of Vericiguat in India CI
Asian Equities Traded in the US as American Depositary Receipts Rebound in Early Wednesday Trading MT
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Thursday Trading MT
Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands MT
Dr. Reddy's Laboratories Limited Enters into Exclusive Distribution Partnership with Sanofi Healthcare India Private Limited CI
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
Dr. Reddy's Labs Secures Marketing Rights to Treatment for Hypovolemic Shock in India, Nepal MT
More news

Latest transcript on Dr. Reddy's Laboratories Limited

1 day-1.22%
1 week-1.47%
Current month-1.15%
1 month-3.39%
3 months+6.93%
6 months+10.03%
Current year+4.94%
More quotes
1 week
6 075.00
Extreme 6075
6 233.95
1 month
6 022.00
Extreme 6022
6 360.05
Current year
5 523.45
Extreme 5523.45
6 505.50
1 year
4 383.40
Extreme 4383.4
6 505.50
3 years
3 655.00
Extreme 3655
6 505.50
5 years
2 352.00
Extreme 2352
6 505.50
10 years
1 888.00
Extreme 1888
6 505.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 -
Director of Finance/CFO - -
Chairman 56 -
Members of the board TitleAgeSince
Chairman 63 -
Chairman 56 -
Director/Board Member 73 -
More insiders
Date Price Change Volume
24-04-12 6,084 -1.22% 21 271
24-04-10 6,159 -0.14% 6,572
24-04-09 6,168 -0.05% 2,386
24-04-08 6,171 -0.06% 5,543
24-04-05 6,175 +0.55% 11,425

Delayed Quote Bombay S.E., April 12, 2024 at 06:00 am EDT

More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,159 INR
Average target price
6,003 INR
Spread / Average Target
-2.54%
Consensus
  1. Stock Market
  2. Equities
  3. DRREDDY Stock